Subbiah Vivek, Viny Aaron D, Rosenblatt Steven, Pohlman Brad, Lichtin Alan, Maciejewski Jaroslaw P
Experimental Hematology and Hematopoiesis Section, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Exp Hematol. 2008 Sep;36(9):1078-83. doi: 10.1016/j.exphem.2008.04.005. Epub 2008 Jun 11.
T-cell large granular lymphocyte leukemia (T-LGL) is a chronic clonal lymphoproliferation of cytotoxic T cells often complicated by cytopenia. Because the outcomes of splenectomy in patients with T-LGL have been only reported sporadically, we objectively assessed the outcomes of splenectomy.
When a cohort of 56 T-LGL patients was analyzed, patients with splenomegaly (n = 34) and had higher frequency of bi- and pancytopenia than patients with no splenomegaly (70% vs 27%; p = 0.001). We identified 15 patients who, in their clinical course, underwent splenectomy and studied their hematological and clinical outcomes.
Indications for splenectomy included symptomatic splenomegaly and/or severe refractory cytopenia. Median spleen weight was 1300 g, consistent with diagnosis of splenomegaly; T-cell receptor (TCR)-gamma rearrangement and typical T-LGL were detected by immunophenotype in all specimens. There was no surgery-related mortality, with the median follow-up and survival of 719 and 498 days, respectively. Two patients died due to causes possibly related to the splenectomized state and/or primary disease. All patients showed lineage-specific hematologic response and achieved transfusion independence; however, precise molecular analysis of TCR and variable chain Vbeta flow cytometry showed persistence of the LGL clones.
We conclude that splenectomy constitutes a viable and safe therapeutic option for patients with T-LGL, splenomegaly, and refractory cytopenia.
T细胞大颗粒淋巴细胞白血病(T-LGL)是一种细胞毒性T细胞的慢性克隆性淋巴细胞增殖性疾病,常伴有血细胞减少。由于T-LGL患者脾切除术的结果仅有零星报道,我们客观评估了脾切除术的效果。
在分析一组56例T-LGL患者时,脾肿大患者(n = 34)的双血细胞减少和全血细胞减少发生率高于无脾肿大患者(70%对27%;p = 0.001)。我们确定了15例在临床过程中接受脾切除术的患者,并研究了他们的血液学和临床结果。
脾切除术的指征包括有症状的脾肿大和/或严重难治性血细胞减少。脾脏重量中位数为1300 g,符合脾肿大诊断;所有标本的免疫表型均检测到T细胞受体(TCR)-γ重排和典型的T-LGL。无手术相关死亡,中位随访时间和生存期分别为719天和498天。2例患者因可能与脾切除状态和/或原发性疾病相关的原因死亡。所有患者均表现出谱系特异性血液学反应并实现了输血独立;然而,TCR的精确分子分析和可变链Vβ流式细胞术显示LGL克隆持续存在。
我们得出结论,对于患有T-LGL、脾肿大和难治性血细胞减少的患者,脾切除术是一种可行且安全的治疗选择。